Skip to main content
. 2021 May 7;24(6):102521. doi: 10.1016/j.isci.2021.102521

Figure 1.

Figure 1

CAN reduced the body and adipose tissue weights, blood lipid/glucose levels, and heart lipid/glucose accumulation, which was not mediated by inhibiting the dietary intake in the HFD/STZ-induced C57BL/6 mice

(A–J) (A) Body weight, (B) energy intake (n = 8), (C) water intake (n = 3), and (D) adipose tissue weight index (n = 10), and (E) serum glucose (n = 10), (F) serum triglyceride (n = 10), (G) serum cholesterol (n = 10), (H) glycogen (n = 5), (I) triglyceride (n = 5), and (J) cholesterol levels in the heart tissues (n = 5) from the HFD/STZ-induced diabetic mice. Data are presented as the mean ± SD (n = 10). #p < 0.05 and ##p < 0.01 versus normal; ∗p < 0.05 and ∗∗p < 0.01 versus HFD/STZ. Normal, normal control group; HFD, high-fat diet; STZ, streptozotocin; CAN, canagliflozin; HFD/STZ, HFD/STZ-induced diabetic control group; HFD/STZ + CAN, canagliflozin-treated HFD/STZ-induced diabetic group.